---
title: "Juvmo (tavapadon) in Parkinson's disease: References"
description: "Reference list for the formulary evidence report on Juvmo (tavapadon, CVL-751) in Parkinson's disease. 221 cited documents."
canonical: "https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/references"
published: "2026-09-27T21:44:59-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Juvmo (tavapadon) in Parkinson's disease: References

<a id="references"></a>

## 5 References

1. [Aamodt et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11469682/)
2. [AAN (2021)](https://www.aan.com/Guidelines/home/GetGuidelineContent/1049)
3. [Aarsland et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2942065/)
4. [AbbVie approval press release (2026)](https://news.abbvie.com/2026-09-28-U-S-FDA-Approves-AbbVies-JUVMO-TM-tavapadon-for-Parkinsons-Disease)
5. [AbbVie Cerevel acquisition completion release (2024)](https://news.abbvie.com/2024-08-01-AbbVie-Completes-Acquisition-of-Cerevel-Therapeutics)
6. [AbbVie comments to ICER (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Parkinsons_Public-Comments-Folio_091626.pdf)
7. [AbbVie earnings call transcript (2026)](https://finance.yahoo.com/quote/ABBV/earnings/ABBV-Q2-2026-earnings_call-656966.html)
8. [AbbVie Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm)
9. [AbbVie JUVMO prescriber access and support page (2026)](https://www.juvmohcp.com/support-access)
10. [AbbVie JUVMO prescriber website (2026)](https://www.juvmohcp.com/)
11. [AbbVie press release (2025)](https://news.abbvie.com/2025-09-26-AbbVie-Submits-New-Drug-Application-to-U-S-FDA-for-Tavapadon-for-the-Treatment-of-Parkinsons-Disease)
12. [AbbVie TEMPO-1 topline release (2024)](https://news.abbvie.com/2024-09-26-AbbVie-Announces-Positive-Topline-Results-from-Phase-3-TEMPO-1-Trial-Evaluating-Tavapadon-as-a-Monotherapy-for-Parkinsons-Disease)
13. [AbbVie TEMPO-2 topline release (2024)](https://news.abbvie.com/2024-12-09-AbbVie-Announces-Positive-Topline-Results-for-the-Phase-3-TEMPO-2-Trial-Evaluating-Tavapadon-as-a-Monotherapy-for-Parkinsons-Disease)
14. [AbbVie third-quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/10/30/abbvie-abbv-q3-2026-earnings-call-transcript/)
15. [AbbVie Wholesale Acquisition Cost Price List (2026)](https://www.e-abbvie.com/Upload_Images/PriceList/Pharmaceutical%20Product%20Wholesaler%20Acquisition%20Cost%20Price%20List.pdf)
16. [Ahlskog and Muenter (2001)](https://pubmed.ncbi.nlm.nih.gov/11391738/)
17. [Albarmawi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10372956/)
18. [Allen et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3606768/)
19. [American Academy of Neurology (2020)](https://www.aan.com/siteassets/home-page/policy-and-guidelines/quality/quality-measures/movement-disorders/2020-parkinson-disease-measurement-set-final.pdf)
20. [Antonini et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18785639/)
21. [Antonini et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30016901/)
22. [Armstrong and Okun (2020)](https://pubmed.ncbi.nlm.nih.gov/32044947/)
23. [Arnold et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12401846/)
24. [ARY News (2026)](https://arynews.tv/tavapadon-us-approves-abbvies-drug-for-parkinsons-disease)
25. [Azilect prescribing information (2020)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a40d0e73-3f9f-4b01-979d-402c9cdaeb60)
26. [Bain Capital (2018)](https://www.baincapital.com/news/bain-capital-and-pfizer-create-cerevel-therapeutics-new-cns-company)
27. [Barone et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19514014/)
28. [Benzinga (2026)](https://www.benzinga.com/news/fda/26/09/62031681/abbvies-new-parkinsons-pill-could-become-a-billion-dollar-drug-analyst-says)
29. [Berg et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26474317/)
30. [Bezard et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10909821/)
31. [Bjornestad et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26585090/)
32. [Bjornestad et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28578818/)
33. [Bloem et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33848468/)
34. [Broen et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27125963/)
35. [CADTH (2020)](https://www.ncbi.nlm.nih.gov/books/NBK564245/)
36. [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22WAC%20Effective%20Date%22%2C%22WAC%20Increase%20Amount%22%2C%22WAC%20After%20Increase%22%20FROM%20%22aca55cd5-a1a7-49cb-a490-997df1e27480%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27Gocovri%25137%20MG%25%27%20UNION%20ALL%20SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22WAC%20Effective%20Date%22%2C%22WAC%20Increase%20Amount%22%2C%22WAC%20After%20Increase%22%20FROM%20%22882bb30d-44ed-48c9-b722-beb5aedc2c1b%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27Nourianz%25%27)
37. [Centers for Medicare and Medicaid Services Part D Spending by Drug for branded adjunctive therapies (2026)](https://data.cms.gov/data-api/v1/dataset/7e0b4365-fd63-4a29-8f5e-e0ac9f66a81b/data?filter%5Bb%5D%5Bcondition%5D%5Bpath%5D=Brnd_Name&filter%5Bb%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Ongentys&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Xadago&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Nourianz&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Neupro&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Gocovri&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Inbrija&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Rytary&filter%5BMftr_Name%5D=Overall&column=Brnd_Name%2CGnrc_Name%2CMftr_Name%2CTot_Spndng_2024%2CTot_Benes_2024%2CAvg_Spnd_Per_Dsg_Unt_Wghtd_2024%2CAvg_Spnd_Per_Bene_2024)
38. [Centers for Medicare and Medicaid Services Part D Spending by Drug for monoamine oxidase B inhibitors, catechol-O-methyltransferase inhibitors, and amantadine (2026)](https://data.cms.gov/data-api/v1/dataset/7e0b4365-fd63-4a29-8f5e-e0ac9f66a81b/data?filter%5Bb%5D%5Bcondition%5D%5Bpath%5D=Brnd_Name&filter%5Bb%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Rasagiline%20Mesylate&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Selegiline%20HCl&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Xadago&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Entacapone&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Carbidopa-Levodopa-Entacapone&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Ongentys&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Amantadine&filter%5Bb%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Gocovri&filter%5BMftr_Name%5D=Overall&column=Brnd_Name%2CGnrc_Name%2CMftr_Name%2CTot_Benes_2024%2CTot_Clms_2024%2CAvg_Spnd_Per_Dsg_Unt_Wghtd_2024)
39. [Cerevel Therapeutics Form 10-K (2024)](https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm)
40. [Cerevel Therapeutics press release (2024)](https://www.globenewswire.com/news-release/2024/04/18/2865216/0/en/Cerevel-Therapeutics-Announces-Positive-Topline-Results-for-Tavapadon-in-Phase-3-Adjunctive-Trial-for-People-Living-with-Parkinson-s-Disease.html)
41. [Cerevel Therapeutics statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/99/NCT04542499/SAP_001.pdf)
42. [Cerevel Therapeutics TEMPO-1 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/93/NCT04201093/Prot_000.pdf)
43. [Cerevel Therapeutics TEMPO-1 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/93/NCT04201093/SAP_001.pdf)
44. [Cerevel Therapeutics TEMPO-2 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/93/NCT04223193/Prot_000.pdf)
45. [Cerevel Therapeutics TEMPO-2 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/93/NCT04223193/SAP_001.pdf)
46. [Cerevel Therapeutics trial protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/99/NCT04542499/Prot_000.pdf)
47. [Chapuis et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15384126/)
48. [Chaudhuri et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6353371/)
49. [ClinicalTrials.gov NCT01981694](https://clinicaltrials.gov/study/NCT01981694)
50. [ClinicalTrials.gov NCT02066909](https://clinicaltrials.gov/study/NCT02066909)
51. [ClinicalTrials.gov NCT02224664](https://clinicaltrials.gov/study/NCT02224664)
52. [ClinicalTrials.gov NCT02224664 results](https://clinicaltrials.gov/study/NCT02224664?tab=results)
53. [ClinicalTrials.gov NCT02373072](https://clinicaltrials.gov/study/NCT02373072)
54. [ClinicalTrials.gov NCT02687542](https://clinicaltrials.gov/study/NCT02687542)
55. [ClinicalTrials.gov NCT02687542 results](https://clinicaltrials.gov/study/NCT02687542?tab=results)
56. [ClinicalTrials.gov NCT02847650](https://clinicaltrials.gov/study/NCT02847650)
57. [ClinicalTrials.gov NCT03121664](https://clinicaltrials.gov/study/NCT03121664)
58. [ClinicalTrials.gov NCT03185481](https://clinicaltrials.gov/study/NCT03185481)
59. [ClinicalTrials.gov NCT04201093](https://clinicaltrials.gov/study/NCT04201093)
60. [ClinicalTrials.gov NCT04201093 results](https://clinicaltrials.gov/study/NCT04201093?tab=results)
61. [ClinicalTrials.gov NCT04223193](https://clinicaltrials.gov/study/NCT04223193)
62. [ClinicalTrials.gov NCT04223193 results](https://clinicaltrials.gov/study/NCT04223193?tab=results)
63. [ClinicalTrials.gov NCT04241393](https://clinicaltrials.gov/study/NCT04241393)
64. [ClinicalTrials.gov NCT04295642](https://clinicaltrials.gov/study/NCT04295642)
65. [ClinicalTrials.gov NCT04542499](https://clinicaltrials.gov/study/NCT04542499)
66. [ClinicalTrials.gov NCT04542499 results](https://clinicaltrials.gov/study/NCT04542499?tab=results)
67. [ClinicalTrials.gov NCT04760769](https://clinicaltrials.gov/study/NCT04760769)
68. [ClinicalTrials.gov NCT05404529](https://clinicaltrials.gov/study/NCT05404529)
69. [ClinicalTrials.gov NCT05404542](https://clinicaltrials.gov/study/NCT05404542)
70. [ClinicalTrials.gov NCT05581823](https://clinicaltrials.gov/study/NCT05581823)
71. [ClinicalTrials.gov NCT05610189](https://clinicaltrials.gov/study/NCT05610189)
72. [ClinicalTrials.gov NCT06895356](https://clinicaltrials.gov/study/NCT06895356)
73. [ClinicalTrials.gov NCT07158827](https://clinicaltrials.gov/study/NCT07158827)
74. [CMS Quality Payment Program measure 291 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_291_MIPSCQM.pdf)
75. [CMS Quality Payment Program measure 293 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_293_MIPSCQM.pdf)
76. [Corvol et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6059034/)
77. [Covington et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27233911/)
78. [Dahodwala et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6174430/)
79. [Dahodwala et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33031604/)
80. [de Bie et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12089898/)
81. [Devraj et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11000704/)
82. [Dickson (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3405828/)
83. [Dodel et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/14531047/)
84. [Entacapone tablets prescribing information (2023)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad4b6d79-efd3-4c43-b4dc-5afdacf939a4)
85. [Etminan et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11665873/)
86. [Fahn et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15590952/)
87. [FDA Novel Drug Therapy Approvals (2026)](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)
88. [Fernandez et al. (2023)](https://doi.org/10.1016/j.parkreldis.2023.105664)
89. [Fernandez et al. (2025)](https://www.neurology.org/doi/10.1212/WNL.0000000000208468)
90. [Fernandez et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13005180/)
91. [Fernandez et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42456682/)
92. [Fernandez et al. supplementary appendix (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/instance/13005180/bin/jamaneurol-e260577-s003.pdf)
93. [Forsaa et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20697051/)
94. [Forsaa et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25603767/)
95. [Fox et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29570866/)
96. [Fox et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12748991/)
97. [Frazer et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9842678/)
98. [Frequin et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38644623/)
99. [Gage et al. (2003)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1738285/)
100. [GBD 2016 Parkinson's Disease Collaborators (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6191528/)
101. [Gerfen (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9892636/)
102. [Gocovri prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bee0631-0028-1314-e063-6394a90aaaed)
103. [Goetz et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/19025984/)
104. [Gonzalez et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9098431/)
105. [Gray et al. (2019)](https://www.mdsabstracts.org/abstract/efficacy-safety-and-tolerability-of-tavapadon-in-subjects-with-early-stage-parkinsons-disease/)
106. [Gros et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40500235/)
107. [Gusovsky et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39475685/)
108. [Hansen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33866942/)
109. [Harrison-Jones et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12446602/)
110. [Hauser et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10803796/)
111. [Hauser et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15390057/)
112. [Hauser et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21437987/)
113. [Hauser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3995302/)
114. [Hauser et al. (2025)](https://www.mdsabstracts.org/abstract/changes-in-motor-states-throughout-the-waking-day-with-tavapadon-in-people-with-parkinsons-disease/)
115. [Hechtner et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24953743/)
116. [Heinzel et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31412427/)
117. [Hellmers et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11805610/)
118. [Hely et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15551331/)
119. [Hely et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18307261/)
120. [Hickey et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28339403/)
121. [Hjalte et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34254292/)
122. [Hjalte et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12528954/)
123. [Höglinger et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38267191/)
124. [Höglinger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12710155/)
125. [Horváth et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26578041/)
126. [Horváth et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28218413/)
127. [Houghton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6839607/)
128. [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Parkinsons-Disease_Evidence-Report_For-Publication_091626.pdf)
129. [ICER public meeting slides (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Parkinsons_Public-Meeting-Slides_100126.pdf)
130. [Jimenez-Shahed et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12255619/)
131. [Johnsrud et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8512608/)
132. [Juvmo prescribing information (2026)](https://www.rxabbvie.com/pdf/juvmo_pi.pdf)
133. [Kalf et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22137459/)
134. [Kalilani et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6874315/)
135. [Kaye et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12468602/)
136. [Kim et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7063985/)
137. [Kordower et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3722357/)
138. [Kowal et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23436720/)
139. [Krishna et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36812432/)
140. [Kwak et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39089982/)
141. [Lange et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13446284/)
142. [Leiter et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375751/)
143. [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10216182/)
144. [Łobińska and Sławek (2026)](https://pubmed.ncbi.nlm.nih.gov/41870480/)
145. [Macleod et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24821648/)
146. [Macleod et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13387983/)
147. [Makkos et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29488318/)
148. [Marras et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6039505/)
149. [Martínez-Fernández et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33369354/)
150. [Martinez-Martin et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21264941/)
151. [Martinez-Martin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6590233/)
152. [Medicaid.gov National Average Drug Acquisition Cost for branded and generic comparators (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions%5B0%5D%5Bproperty%5D=ndc_description&conditions%5B0%5D%5Boperator%5D=in&conditions%5B0%5D%5Bvalue%5D%5B%5D=ONGENTYS%2050%20MG%20CAPSULE&conditions%5B0%5D%5Bvalue%5D%5B%5D=XADAGO%20100%20MG%20TABLET&conditions%5B0%5D%5Bvalue%5D%5B%5D=RYTARY%20ER%2036.25%20MG-145%20MG%20CAP&conditions%5B0%5D%5Bvalue%5D%5B%5D=PRAMIPEXOLE%201%20MG%20TABLET&conditions%5B0%5D%5Bvalue%5D%5B%5D=ROPINIROLE%20HCL%203%20MG%20TABLET&conditions%5B0%5D%5Bvalue%5D%5B%5D=CARBIDOPA-LEVODOPA%2025-100%20TAB&conditions%5B1%5D%5Bproperty%5D=as_of_date&conditions%5B1%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bvalue%5D=2026-09-23&limit=100&properties%5B%5D=ndc_description&properties%5B%5D=ndc&properties%5B%5D=nadac_per_unit&properties%5B%5D=pricing_unit&properties%5B%5D=effective_date&properties%5B%5D=as_of_date)
153. [Medicaid.gov National Average Drug Acquisition Cost for rotigotine, rasagiline, selegiline, entacapone, and amantadine (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions%5B0%5D%5Bproperty%5D=ndc_description&conditions%5B0%5D%5Boperator%5D=in&conditions%5B0%5D%5Bvalue%5D%5B%5D=NEUPRO%202%20MG%2F24%20HR%20PATCH&conditions%5B0%5D%5Bvalue%5D%5B%5D=RASAGILINE%20MESYLATE%201%20MG%20TAB&conditions%5B0%5D%5Bvalue%5D%5B%5D=SELEGILINE%20HCL%205%20MG%20CAPSULE&conditions%5B0%5D%5Bvalue%5D%5B%5D=ENTACAPONE%20200%20MG%20TABLET&conditions%5B0%5D%5Bvalue%5D%5B%5D=CARBIDOPA-LEVODOPA-ENTACAPONE%2025-100-200%20MG%20TAB&conditions%5B0%5D%5Bvalue%5D%5B%5D=AMANTADINE%20100%20MG%20CAPSULE&conditions%5B1%5D%5Bproperty%5D=as_of_date&conditions%5B1%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bvalue%5D=2026-09-23&limit=100&properties%5B%5D=ndc_description&properties%5B%5D=ndc&properties%5B%5D=nadac_per_unit&properties%5B%5D=pricing_unit&properties%5B%5D=effective_date&properties%5B%5D=as_of_date)
154. [Mirapex prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020667s044lbl.pdf)
155. [Neupro prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021829s021s022lbl.pdf)
156. [NeurologyLive (2025)](https://www.neurologylive.com/view/parkinson-agent-tavapadon-continued-efficacy-safety-phase-3-tempo-4-trial)
157. [Nguyen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12084000/)
158. [NICE (2017)](https://www.nice.org.uk/guidance/ng71/chapter/Recommendations)
159. [Nourianz prescribing information (2023)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7d008cb-b273-4049-a5d2-9c6902910d58)
160. [Noyes et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15358996/)
161. [Ondo et al. (2026)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-004053.html)
162. [Ongentys prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a511a531-112e-43f8-a43f-5334b0efe979)
163. [Pahwa and Isaacson (2020)](https://pubmed.ncbi.nlm.nih.gov/33113598/)
164. [Pahwa et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37877478/)
165. [Pahwa et al. (2025)](https://www.mdsabstracts.org/abstract/tavapadon-is-not-associated-with-increased-daytime-sleepiness-in-people-with-parkinsons-disease/)
166. [Pahwa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13005179/)
167. [Palma and Gomez Casanovas (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13389945/)
168. [Pastino et al. (2022)](https://www.neurology.org/doi/10.1212/WNL.98.18_supplement.2728)
169. [PD MED Collaborative Group (2014)](https://pubmed.ncbi.nlm.nih.gov/24928805/)
170. [Pharmaceutical Technology (2024)](https://www.pharmaceutical-technology.com/data-insights/tavapadon-abbvie-net-present-value/)
171. [Poewe et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28332488/)
172. [Postuma et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26474316/)
173. [Postuma et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30145797/)
174. [Postuma et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6391615/)
175. [Pringsheim et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8672433/)
176. [Quintas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11145110/)
177. [Rabinak and Nirenberg (2010)](https://pubmed.ncbi.nlm.nih.gov/20065130/)
178. [Rajagopalan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37936540/)
179. [Ramanzini et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489609/)
180. [Rascol and Fabbri (2026)](https://pubmed.ncbi.nlm.nih.gov/42456666/)
181. [Rashid et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42601529/)
182. [Reijnders et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17987654/)
183. [Requip prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020658s038lbl.pdf)
184. [Reuters (2026)](https://srnnews.com/us-fda-approves-abbvies-drug-for-parkinsons-disease/)
185. [Riesenberg et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066585/)
186. [Rizos et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25269446/)
187. [Rizzo et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26764028/)
188. [Rong et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34706971/)
189. [Rosqvist et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13443338/)
190. [Safarpour et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4534080/)
191. [Sahlholm et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12232300/)
192. [Sako et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10584871/)
193. [Schini et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31790846/)
194. [Schrag et al. (2000)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1737100/)
195. [Schuepbach et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23406026/)
196. [Selegiline hydrochloride capsules prescribing information (2014)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1924db3d-6a16-4496-cfd0-6903be146925)
197. [Siderowf et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10627170/)
198. [Simon et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6905381/)
199. [Simuni et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38267190/)
200. [Sisodia et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10862331/)
201. [Sohur et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6283789/)
202. [Stocchi et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20582993/)
203. [Su et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11881235/)
204. [Thach et al. (2021a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7846980/)
205. [Thach et al. (2021b)](https://pubmed.ncbi.nlm.nih.gov/33819121/)
206. [Thach et al. (2021c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8809356/)
207. [The Lewin Group (2026)](https://www.michaeljfox.org/sites/default/files/media/document/Economic%20Burden%20of%20Parkinson%E2%80%99s%20and%20Atypical%20Parkinsonism%20in%20the%20United%20States_0.pdf)
208. [Torres-Russotto et al. (2026)](https://www.neurology.org/doi/10.1212/WNL.0000000000216870)
209. [Verschuur et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30673543/)
210. [Wang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935681/)
211. [Weaver et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2814800/)
212. [Weintraub et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20457959/)
213. [Willis et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3599783/)
214. [Willis et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9755252/)
215. [World Parkinson Congress (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13360760/)
216. [Xadago prescribing information (2021)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4d65f28-983f-42b4-bb23-023ae0fe81b2)
217. [Yang et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7347582/)
218. [Yao et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36470230/)
219. [Young et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31971364/)
220. [Zhang et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27770275/)
221. [Zhao et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38573387/)

## Related pages
- [Juvmo (tavapadon): Parkinson's disease](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease) · [Markdown](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease.md)
- [Juvmo (tavapadon) in Parkinson's disease: Terms and abbreviations](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/terms-and-abbreviations.md)
- [Juvmo (tavapadon): Parkinson's disease](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/executive-summary.md)
- [Juvmo (tavapadon) in Parkinson's disease: Product information and disease description](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/product-information-and-disease-description.md)
- [Juvmo (tavapadon) in Parkinson's disease: Clinical evidence](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/clinical-evidence.md)
- [Juvmo (tavapadon) in Parkinson's disease: Economic information and modeling report](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/economics.md)
- [Juvmo (tavapadon) in Parkinson's disease: new drug review](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/monograph/review) · [Markdown](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/monograph/review.md)
- [Juvmo (tavapadon) in Parkinson's disease: prevalence by geography](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/prevalence) · [Markdown](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/prevalence.md)
- [Juvmo (tavapadon) in Parkinson's disease: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/cost-effectiveness-analyses.md)
- [Juvmo (tavapadon) in Parkinson's disease: interactive budget impact model](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/budget-impact-model) · [Markdown](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/budget-impact-model.md)
